ABSTRACT
BACKGROUND: Multiple system atrophy (MSA) is a neurodegenerative disease. It has a fast progression, so early diagnosis is decisive. Two functional imaging tests can be involved in its diagnosis: [123I]Ioflupane SPECT and [123I]MIBG scintigraphy. Our aim is to comparatively analyze the diagnostic performance of both techniques. METHODS: 46 patients (24 males and 22 females) with MSA underwent [123I]Ioflupane SPECT and [123I]MIBG scintigraphy. In each of these techniques, qualitative assessment was compared with quantitative assessment. RESULTS: SPECT visual assessment was positive in 93.5% of subjects (S = 95.24%; PPV = 93.02%). A cut-off of 1.363 was established for overall S/O index (S = 85.7%, E = 100%). Visual assessment of scintigraphy was positive in 73.1% (S = 78.57%, PPV = 94.29%). For the delayed heart/medistinum ratio (HMR) a cut-off of 1.43 (S = 85.3, E = 100%) was obtained. For each unit increase in delayed HMR, the suspicion of MSA increased by 1.58 (OR = 1.58, p < 0.05). The quantitative assessment showed an association with the visual assessment for each technique (p < 0.05). CONCLUSIONS: Both tests are useful in MSA diagnosis. Comparatively, we did not observe a clear superiority of either. Striatal and myocardial deterioration do not evolve in parallel. Qualitative assessment is crucial in both techniques, together with the support of quantitative analysis. Delayed HMR shows a direct relationship with the risk of MSA.
ABSTRACT
BACKGROUND: Multiple system atrophy (MSA) is subdivided into two types: MSA-P (parkinsonian) and MSA-C (cerebellar). Brain SPECT allows for the detection of nigrostriatal involvement, even in the early stages. To date, the scientific literature does not show a consensus on how to follow-up MSA, especially MSA-C. Our aim was to analyze the diagnostic effectiveness of repeat [123I]Ioflupane SPECT for the follow-up of MSA. METHODS: A longitudinal observational study on 22 MSA patients (11 males and 11 females). RESULTS: Significant changes were obtained in the quantitative SPECT assessments in the three Striatum/Occipital indices. The qualitative SPECT diagnosis did not show differences between the initial and evolving SPECT, but the neurologist's clinical suspicion did. Our results showed a brain deterioration of around 31% at 12 months, this being the optimal cut-off for differentiating a diseased subject (capable of solving diagnostic error rate). Previous imaging tests were inconclusive, as they showed less deterioration in the SPECT and quantitative assessments with respect to the group of confirmed patients. Repeated SPECT increased the diagnostic sensitivity (50% vs. 75%) and positive predictive value (72.73% vs. 77%). In addition, repeated SPECT proved decisive in the diagnosis of initial inconclusive cases. CONCLUSION: Repeat SPECT at 12 months proves useful in the diagnosis and follow-up of MSA.
ABSTRACT
BACKGROUND: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder that has no curative treatment. Diagnosis is based on a set of criteria established by Gilman (1998 and 2008) and recently updated by Wenning (2022). We aim to determine the effectiveness of [123I]Ioflupane SPECT in MSA, especially at the initial clinical suspicion. METHODS: A cross-sectional study of patients at the initial clinical suspicion of MSA, referred for [123I]Ioflupane SPECT. RESULTS: Overall, 139 patients (68 men, 71 women) were included, 104 being MSA-probable and 35 MSA-possible. MRI was normal in 89.2%, while SPECT was positive in 78.45%. SPECT showed high sensitivity (82.46%) and positive predictive value (86.24), reaching maximum sensitivity in MSA-P (97.26%). Significant differences were found when relating both SPECT assessments in the healthy-sick and inconclusive-sick groups. We also found an association when relating SPECT to the subtype (MSA-C or MSA-P), as well as to the presence of parkinsonian symptoms. Lateralization of striatal involvement was detected (left side). CONCLUSIONS: [123I]Ioflupane SPECT is a useful and reliable tool for diagnosing MSA, with good effectiveness and accuracy. Qualitative assessment shows a clear superiority when distinguishing between the healthy-sick categories, as well as between the parkinsonian (MSA-P) and cerebellar (MSA-C) subtypes at initial clinical suspicion.
ABSTRACT
Fundamento y objetivo: Evaluar el estado funcional de la vía nigro-estriada utilizando N-ω-fluoropropil-2ß-carbometoxi-3ß-(4-Iodofenil) nortropano (FP-CIT-I-123) en pacientes con diagnóstico clínico de atrofia multisistémica (AMS) subtipo C. Pacientes y método: Se incluyen 10 pacientes con diagnóstico clínico de AMS-C y se comparan con 10 diagnosticados de temblor esencial (controles) y otros 10 con enfermedad de Parkinson (EP). Los estudios son valorados mediante el índice estriado/occipital (E/O), calculando la validez diagnóstica del procedimiento mediante curvas ROC. Resultados: El valor medio (DE) del índice E/O fue de 1,48 (0,23), 1,59 (0,17) y 1,22 (0,16), correspondientes, respectivamente, a AMS-C, controles (p=0,25) y EP (p=0,00). Curva ROC: Az: 0,650; sensibilidad: 0,50; especificidad: 0,80. La correlación del estudio con FP-CIT y la clínica predominante mostró 4 pacientes con clínica parkinsoniana y estudio patológico, 4 sin clínica parkinsoniana y estudio normal, uno con clínica parkinsoniana y estudio normal, y uno sin clínica parkinsoniana y estudio patológico. Conclusiones: El estudio con FP-CIT no permite descartar totalmente la existencia de una AMS-C. Desde el punto de vista funcional, no siempre parece existir congruencia entre el estado de la vía nigro-estriada y la existencia de parkinsonismo (AU)
Background and objective: To assess the functional state of nigro-striatal pathway using FP-CIT-I-123 in patients with clinical diagnosis of Multiple System Atrophy (MSA) subtype C. Patients and methods: We included 10 patients with a clinical diagnosis of MSA-C and compared them with 10 patients diagnosed with essential tremor (controls) and 10 with Parkinson Disease (PD). The studies are evaluated by the striatum/occipital index (S/O). We calculated the diagnostic validity of the procedure by ROC curve analysis. Results: The average value of the S/O index showed a mean of 1.48 (0.23), 1.59 (0.17) and 1.22 (0.16) respectively for MSA-C, control group (p=0.25) and PD (p=0.00). ROC curve analysis: Az: 0.650; sensitivity: 0.50; specificity: 0.80. The comparison between the results of FP-CIT and clinical manifestations showed: 4 patients with parkinsonism (PK) and pathological study; 4 without PK and normal study; 1 with PK and normal study and 1 without PK and pathological study. Conclusions: FP-CIT study does not exclude completely the existence of an MSA-C. From a functional point of view, there does not always seem to be a consistency between the state of the nigro-striatal pathway and the existence of parkinsonism (AU)
Subject(s)
Humans , Olivopontocerebellar Atrophies/physiopathology , Tomography, Emission-Computed, Single-Photon/methods , Dopamine Plasma Membrane Transport Proteins/analysis , Corpus Striatum/physiopathologyABSTRACT
BACKGROUND AND OBJECTIVE: To assess the functional state of nigro-striatal pathway using FP-CIT-I-123 in patients with clinical diagnosis of Multiple System Atrophy (MSA) subtype C. PATIENTS AND METHODS: We included 10 patients with a clinical diagnosis of MSA-C and compared them with 10 patients diagnosed with essential tremor (controls) and 10 with Parkinson Disease (PD). The studies are evaluated by the striatum/occipital index (S/O). We calculated the diagnostic validity of the procedure by ROC curve analysis. RESULTS: The average value of the S/O index showed a mean of 1.48 (0.23), 1.59 (0.17) and 1.22 (0.16) respectively for MSA-C, control group (p=0.25) and PD (p=0.00). ROC curve analysis: Az: 0.650; sensitivity: 0.50; specificity: 0.80. The comparison between the results of FP-CIT and clinical manifestations showed: 4 patients with parkinsonism (PK) and pathological study; 4 without PK and normal study; 1 with PK and normal study and 1 without PK and pathological study. CONCLUSIONS: FP-CIT study does not exclude completely the existence of an MSA-C. From a functional point of view, there does not always seem to be a consistency between the state of the nigro-striatal pathway and the existence of parkinsonism.
Subject(s)
Carbon Radioisotopes , Corpus Striatum/diagnostic imaging , Dopamine Plasma Membrane Transport Proteins/analysis , Fluorine Radioisotopes , Iodine Radioisotopes , Multiple System Atrophy/diagnostic imaging , Parkinsonian Disorders/diagnostic imaging , Radiopharmaceuticals , Tomography, Emission-Computed, Single-Photon , Tropanes , Aged , Aged, 80 and over , Carbon Radioisotopes/pharmacokinetics , Cerebellum/physiopathology , Corpus Striatum/chemistry , Essential Tremor/diagnostic imaging , Female , Fluorine Radioisotopes/pharmacokinetics , Humans , Iodine Radioisotopes/pharmacokinetics , Male , Middle Aged , Multiple System Atrophy/classification , Multiple System Atrophy/complications , Multiple System Atrophy/metabolism , Nerve Tissue Proteins/analysis , Parkinson Disease/diagnostic imaging , Parkinsonian Disorders/etiology , ROC Curve , Radiopharmaceuticals/pharmacokinetics , Tropanes/pharmacokineticsABSTRACT
OBJECTIVE: To compare various published thallium-201 uptake indexes in the differential diagnosis in recurrent brain gliomas. MATERIAL AND METHODS: Thallium-201 SPECT studies were performed in 79 patients previously treated for glial tumor with clinical or radiologic suspicion of recurrence. Regions of interest were established in the tumor area and in other sites with normal uptake. RESULTS: A high linear correlation was found among indices, with significant differences between all index pairs. Logistic regression analysis confirmed high colinearity among indexes, with index 3 (mean counts in tumor/mean counts in contralateral hemisphere) showing a slightly superior predictive power to differentiate tumor absence from tumor presence and tumor absence from low-grade recurrence. These findings were supported by analysis of areas under the ROC curve. CONCLUSIONS: The uptake indices studied behave similarly in the evaluation of a possible recurrence of a glial brain lesion and should be considered complementary to visual evaluation as a semi-objective tool.
Subject(s)
Brain Neoplasms/diagnostic imaging , Glioma/diagnostic imaging , Thallium Radioisotopes , Tomography, Emission-Computed, Single-Photon , Adult , Aged , Brain Neoplasms/metabolism , Brain Neoplasms/radiotherapy , Brain Neoplasms/surgery , Child , Diagnosis, Differential , Female , Glioma/metabolism , Glioma/radiotherapy , Glioma/surgery , Humans , Male , Middle Aged , ROC Curve , Recurrence , Thallium Radioisotopes/metabolism , Young AdultABSTRACT
Objetivos: Comparar los resultados de tiroglobulina obtenidos ante estimulación con tirotropina recombinante humana (rhTSH) con fines diagnósticos y tras privación hormonal previa a la terapia con 131I. Pacientes y método: Se evaluó a 31 pacientes en seguimiento por cáncer diferenciado de tiroides (CDT) a los que se indicó dosis terapéutica de 131I. Fueron sometidos de forma consecutiva a ambos protocolos de estimulación, y el tratamiento con radioyodo distó 1-2 meses del procedimiento diagnóstico con rhTSH. Se realizaron determinaciones analíticas de TSH, tiroglobulina (Tg) y anticuerpos anti-Tg por métodos inmunométricos. Resultados: Las medianas de Tg obtenidas tras rhTSH y privación fueron de 1,10 y 1,80 ng/ml, respectivamente. Analizados como positivos o negativos, dichos valores mostraron un índice kappa de concordancia de 0,633. Los casos discordantes mostraron una mayor elevación de Tg en estímulo con rhTSH (3 casos) y sólo en 1 caso se obtuvo un resultado negativo con estimulación con rhTSH que luego se positivizó en la dosis ablativa. Conclusiones: El estímulo con rhTSH consigue elevaciones diagnósticas de TSH en todos los casos aplicados. Los valores de Tg obtenidos con ambos estímulos muestran un grado de concordancia elevado (AU)
Objectives: To compare the results of thyroglobulin (Tg) determination after diagnostic recombinant human thyroid-stimulating hormone (rhTSH) stimulation and after hormone withdrawal prior to 131I therapy. Patients and method: Thirty-one patients followed-up for differentiated thyroid cancer were evaluated. In all patients 131I therapy was indicated. All patients underwent both stimulation methods, with an interval of 1-2 months between diagnostic rhTSH administration and radioiodine therapy. Laboratory determinations of TSH, Tg and Tg antibodies were carried out by immunometric methods. Results: Median Tg values obtained after rhTSH stimulation and hormone withdrawal were 1.10 and 1.80 ng/ml, respectively. Considered as positive or negative, these values showed a kappa value of 0.633. Discordant cases showed greater elevation after rhTSH stimulation (3 patients). Only one patient showed a negative result after rhTSH stimulation, which was then positive after the ablative dose. Conclusions: Stimulus with rhTSH achieved diagnostic elevations of TSH in all patients. Tg levels after both stimulation methods showed a high degree of agreement (AU)
Subject(s)
Male , Female , Adult , Middle Aged , Humans , Thyroglobulin/blood , Thyrotropin , 3-Iodobenzylguanidine/therapeutic use , Antineoplastic Agents/therapeutic use , Thyroid Neoplasms/blood , Thyroid Neoplasms/drug therapy , Follow-Up Studies , Reference Values , Stimulation, Chemical , Prognosis , Neoplasm StagingABSTRACT
BACKGROUND: Recent advances in hepatobiliary surgery have underscored the need for presurgical diagnosis of gallbladder cancer. Frequently, clinical presentation, biochemical analysis, and structural ultrasound or computed axial tomography images do not enable definitive differentiation of cholecystitis or cholethiasis from gallbladder cancer. The aim of this study was to evaluate the role of fludeoxy glucose-positron-emission tomography (FDG-PET) in establishing the benign or malignant nature of gallbladder lesions. METHODS: A case series of 16 patients with clinical symptoms suggestive of biliary colic or chronic cholecystitis and with inconclusive ultrasound and/or computed axial tomography findings for presence of gallbladder cancer were studied by FDG-PET. RESULTS: FDG-PET showed a sensitivity of 0.80, a specificity of 0.82, and positive and negative predictive values of 0.67 and 0.90, respectively. There was 1 false- negative result in 1 patient with mucinous adenocarcinoma and 2 false-positive results in 1 patient with tuberculoid granulomatous reaction and 1 patient with polypoid lesion with adenomyomatosis. CONCLUSIONS: FDG-PET may be of utility to establish the diagnosis of gallbladder cancer in patients with nonspecific clinical and imaging findings.
